{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:16Z","timestamp":1785521836884,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03627-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:06:29Z","timestamp":1779264389000},"page":"3473-3487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Ke","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"3627_CR1","unstructured":"Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for prevention diagnosis and management of COPD: 2026 report. 2025. https:\/\/goldcopd.org\/2026-gold-report\/. Accessed Jan 21, 2026."},{"issue":"10131","key":"3627_CR2","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(18)30841-9","volume":"391","author":"C Wang","year":"2018","unstructured":"Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706\u201317.","journal-title":"Lancet"},{"issue":"2","key":"3627_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1081\/COPD-120039210","volume":"1","author":"WC Tan","year":"2004","unstructured":"Tan WC. Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease. COPD. 2004;1(2):225\u201347.","journal-title":"COPD"},{"key":"3627_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105938","volume":"166","author":"CF Vogelmeier","year":"2020","unstructured":"Vogelmeier CF, Rom\u00e1n-Rodr\u00edguez M, Singh D, Han MK, Rodr\u00edguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938.","journal-title":"Respir Med"},{"issue":"6","key":"3627_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","volume":"3","author":"S Pascoe","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435\u201342.","journal-title":"Lancet Respir Med"},{"issue":"10125","key":"3627_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076\u201384.","journal-title":"Lancet"},{"issue":"18","key":"3627_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"3627_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase\u00a03 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3627_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"10048","key":"3627_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963\u201373.","journal-title":"Lancet"},{"key":"3627_CR11","doi-asserted-by":"publisher","first-page":"1147985","DOI":"10.3389\/fphar.2023.1147985","volume":"14","author":"L Lin","year":"2023","unstructured":"Lin L, Liu C, Cheng W, et al. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: a prospective observational study in China. Front Pharmacol. 2023;14:1147985.","journal-title":"Front Pharmacol"},{"key":"3627_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.753653","volume":"12","author":"W Cheng","year":"2021","unstructured":"Cheng W, Duan J, Zhou A, et al. Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study. Front Pharmacol. 2021;12:753653.","journal-title":"Front Pharmacol"},{"key":"3627_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/COPD.S308911","volume":"16","author":"WC Huang","year":"2021","unstructured":"Huang WC, Chen CY, Liao WC, et al. A real world study to assess the effectiveness of switching to once daily closed triple therapy from mono\/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1555\u201368.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3627_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/07853890.2023.2192519","volume":"55","author":"Q Song","year":"2023","unstructured":"Song Q, Lin L, Zhou A, et al. The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study. Ann Med. 2023;55(1):1317\u201324.","journal-title":"Ann Med"},{"key":"3627_CR15","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04202","volume":"14","author":"L Lin","year":"2024","unstructured":"Lin L, Song Q, Cheng W, et al. Impact of exacerbation history on future risk and treatment outcomes in chronic obstructive pulmonary disease patients: a prospective cohort study based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) A and B classifications. J Glob Health. 2024;14:04202.","journal-title":"J Glob Health"},{"key":"3627_CR16","doi-asserted-by":"publisher","first-page":"175346662311673","DOI":"10.1177\/17534666231167353","volume":"17","author":"T Yang","year":"2023","unstructured":"Yang T, Cai B, Cao B, et al. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Ther Adv Respir Dis. 2023;17:17534666231167352.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"3627_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12931-022-02021-w","volume":"23","author":"T Yang","year":"2022","unstructured":"Yang T, Cai B, Cao B, et al. Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study. Respir Res. 2022;23(1):106.","journal-title":"Respir Res"},{"issue":"7","key":"3627_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.arbres.2024.03.029","volume":"60","author":"X Wu","year":"2024","unstructured":"Wu X, Deng Z, Wu F, et al. Clinical characteristics and 2-year outcomes of chronic obstructive pulmonary disease patients with high blood eosinophil counts: a population-based prospective cohort study in China. Arch Bronconeumol. 2024;60(7):402\u20139.","journal-title":"Arch Bronconeumol"},{"key":"3627_CR19","doi-asserted-by":"publisher","first-page":"175346662312137","DOI":"10.1177\/17534666231213715","volume":"17","author":"Q Song","year":"2023","unstructured":"Song Q, Cheng W, Liu C, et al. The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports. Ther Adv Respir Dis. 2023;17:17534666231213716.","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"3627_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2304107","volume":"55","author":"X Li","year":"2023","unstructured":"Li X, Song Q, Cheng W, et al. The clinical characteristics and outcomes of different inhaled therapies in chronic obstructive pulmonary disease patients with frequent cough. Ann Med. 2023;55(2):2304107.","journal-title":"Ann Med"},{"key":"3627_CR21","doi-asserted-by":"publisher","first-page":"04055","DOI":"10.7189\/jogh.15.04055","volume":"15","author":"Q Song","year":"2025","unstructured":"Song Q, Lin L, Li T, et al. The treatment responses among different inhalation therapies for GOLD group E patients with chronic obstructive pulmonary disease. J Glob Health. 2025;15:04055.","journal-title":"J Glob Health"},{"key":"3627_CR22","doi-asserted-by":"publisher","first-page":"175346662412922","DOI":"10.1177\/17534666241292242","volume":"18","author":"LW Wu","year":"2024","unstructured":"Wu LW, Lin TC, Lin TH, et al. Comparative effectiveness and safety of escalating to triple therapy versus switching to dual bronchodilators after discontinuing LABA\/ICS in patients with COPD: a retrospective cohort study. Ther Adv Respir Dis. 2024;18:17534666241292242.","journal-title":"Ther Adv Respir Dis"},{"issue":"12","key":"3627_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"3627_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/crj.13129","volume":"14","author":"SP Hogea","year":"2020","unstructured":"Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183\u201397.","journal-title":"Clin Respir J"},{"key":"3627_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/COPD.S270729","volume":"15","author":"H Dong","year":"2020","unstructured":"Dong H, Hao Y, Li D, et al. Risk factors for acute exacerbation of chronic obstructive pulmonary disease in industrial regions of China: a multicenter cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2020;15:2249\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"3627_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.5588\/ijtld.24.0255","volume":"28","author":"W Yu","year":"2024","unstructured":"Yu W, Lan Y, Sun D, et al. Risk factors for severe COPD exacerbation in Chinese adults. Int J Tuberc Lung Dis. 2024;28(12):578\u201384.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"3627_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","volume":"23","author":"JR Hurst","year":"2022","unstructured":"Hurst JR, Han MK, Singh B, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23(1):213.","journal-title":"Respir Res"},{"issue":"4","key":"3627_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.chest.2019.04.107","volume":"156","author":"D Stolz","year":"2019","unstructured":"Stolz D, Kostikas K, Loefroth E, et al. Differences in COPD exacerbation risk between women and men: analysis from the UK Clinical Practice Research Datalink Data. Chest. 2019;156(4):674\u201384.","journal-title":"Chest"},{"issue":"9","key":"3627_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1164\/rccm.201601-0015ED","volume":"193","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk. Maybe just for some? Am J Respir Crit Care Med. 2016;193(9):937\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"3627_CR30","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2147\/COPD.S129787","volume":"12","author":"M Zysman","year":"2017","unstructured":"Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3627_CR31","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.vhri.2020.07.535","volume":"22","author":"C Xing","year":"2020","unstructured":"Xing C, Wang X, Zhou Y, Dong F. PRS21 the complexity and medical resources for COPD patients in China [Abstract]. Value Health Reg Issues. 2020;22:S102\u20133.","journal-title":"Value Health Reg Issues"},{"key":"3627_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107516","volume":"222","author":"FWS Ko","year":"2024","unstructured":"Ko FWS, Xu X, Chau C, Navarro A, Hui DSC, Milea D. Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong. Respir Med. 2024;222:107516.","journal-title":"Respir Med"},{"key":"3627_CR33","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2147\/COPD.S322036","volume":"16","author":"CF Vogelmeier","year":"2021","unstructured":"Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich FW. COPD exacerbation history and impact on future exacerbations\u20148-year retrospective observational database cohort study from Germany. Int J Chron Obstruct Pulmon Dis. 2021;16:2407\u201317.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3627_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12931-022-02136-0","volume":"23","author":"CH Lee","year":"2022","unstructured":"Lee CH, Kim MS, Yeo SH, et al. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea. Respir Res. 2022;23(1):231.","journal-title":"Respir Res"},{"key":"3627_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/COPD.S378867","volume":"18","author":"NA Hanania","year":"2023","unstructured":"Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M. COPD exacerbations, costs, and health care resource utilization before and after initiation of fluticasone furoate\/umeclidinium\/vilanterol in routine care in the USA. Int J Chron Obstruct Pulmon Dis. 2023;18:407\u201318.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"3627_CR36","first-page":"791","volume":"29","author":"S Sethi","year":"2023","unstructured":"Sethi S, Palli SR, Bengtson LGS, et al. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide\/olodaterol or fluticasone furoate\/umeclidinium\/vilanterol. J Manag Care Spec Pharm. 2023;29(7):791\u2013806.","journal-title":"J Manag Care Spec Pharm"},{"key":"3627_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2147\/COPD.S386962","volume":"18","author":"S Sethi","year":"2023","unstructured":"Sethi S, Clark B, Bengtson LGS, et al. Healthcare resource utilization, cost and clinical outcomes in patients diagnosed with COPD initiating tiotropium bromide\/olodaterol versus fluticasone furoate\/umeclidinium\/vilanterol based on exacerbation history. Int J Chron Obstruct Pulmon Dis. 2023;18:625\u201341.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3627_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/03007995.2020.1844646","volume":"37","author":"J Zheng","year":"2021","unstructured":"Zheng J, Zhong N, Wang C, et al. Single inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. Curr Med Res Opin. 2021;37(1):145\u201355.","journal-title":"Curr Med Res Opin"},{"key":"3627_CR39","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2147\/COPD.S419119","volume":"18","author":"A Czira","year":"2023","unstructured":"Czira A, Akiyama S, Ishii T, et al. Benefit of prompt vs delayed initiation of triple therapy following an exacerbation in patients with COPD in Japan: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2023;18:2933\u201353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3627_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107090","volume":"206","author":"H Ruan","year":"2023","unstructured":"Ruan H, Zhang H, Wang J, Zhao H, Han W, Li J. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2023;206:107090.","journal-title":"Respir Med"},{"key":"3627_CR41","unstructured":"Chongqing Municipal Bureau of Statistics. Statistical Bulletin on the National Economic and Social Development of Chongqing Municipality in 2022. https:\/\/tjj.cq.gov.cn\/zwgk_233\/fdzdgknr\/tjxx\/sjzl_55471\/tjgb_55472\/202303\/t20230317_11775723.html. Accessed Apr 24, 2025."},{"issue":"09","key":"3627_CR42","first-page":"66","volume":"34","author":"J Li","year":"2015","unstructured":"Li J, Feng R, Cui Y, Liu S, Zeng Z, Wang X. Analysis of the economic burden of drug treatment for patients with chronic obstructive pulmonary disease in tertiary hospitals in China. Chin Health Econ. 2015;34(09):66\u20138.","journal-title":"Chin Health Econ"},{"key":"3627_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/COPD.S276476","volume":"16","author":"S Gong","year":"2021","unstructured":"Gong S, Hu H, Zhao K, Yang T. Cost-effectiveness of dual bronchodilator indacaterol\/glycopyrronium for COPD treatment in China. Int J Chron Obstruct Pulmon Dis. 2021;16:433\u201341.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3627_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/13696998.2022.2043633","volume":"25","author":"L Wang","year":"2022","unstructured":"Wang L, Gu W, Zhang X, et al. How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate\/formoterol for the treatment of COPD. J Med Econ. 2022;25(1):356\u201366.","journal-title":"J Med Econ"},{"key":"3627_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/17534666231158283","volume":"17","author":"T Yang","year":"2023","unstructured":"Yang T, Cai B, Cao B, et al. Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Ther Adv Respir Dis. 2023;17:17534666231158283.","journal-title":"Ther Adv Respir Dis"},{"key":"3627_CR46","doi-asserted-by":"crossref","unstructured":"Tur\u00e9gano\u2011Yedro M, Trillo\u2011Calvo E, Navarro i Ros F, et al. Inhaler adherence in COPD: a crucial step towards the correct treatment. Int J Chron Obstruct Pulmon Dis. 2023;18:2887\u201393.","DOI":"10.2147\/COPD.S431829"},{"key":"3627_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11606-023-08378-y","volume":"39","author":"J Wu","year":"2024","unstructured":"Wu J, Meng W, Ma Y, et al. Errors and adherence to inhaled medications in Chinese adults with COPD. J Gen Intern Med. 2024;39:69\u201376.","journal-title":"J Gen Intern Med"},{"key":"3627_CR48","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2147\/PPA.S413948","volume":"17","author":"X Tan","year":"2023","unstructured":"Tan X, Liu S, Huang L, et al. Correlation analysis of the therapy adherence to long-acting inhalers among patients with stable COPD. Patient Prefer Adherence. 2023;17:1467\u201375.","journal-title":"Patient Prefer Adherence"},{"key":"3627_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17534666231178692","volume":"17","author":"T Yang","year":"2023","unstructured":"Yang T, Cai B, Cao B, et al. REALizing and improving management of stable COPD in China: results of a multicentre, prospective, observational study (REAL). Ther Adv Respir Dis. 2023;17:1\u201316.","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"3627_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088887","volume":"15","author":"L Du","year":"2025","unstructured":"Du L, Wu X, Zhao S, et al. Quantitative CT imaging characteristics of patients with chronic obstructive pulmonary disease with different eosinophil levels: a retrospective observational study using linked data from a tertiary hospital in China. BMJ Open. 2025;15(2):e088887.","journal-title":"BMJ Open"},{"issue":"2","key":"3627_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000535989","volume":"103","author":"M Yang","year":"2024","unstructured":"Yang M, Lv Y, Tang S, et al. Blood eosinophil count and its determinants in a Chinese population-based cohort. Respiration. 2024;103(2):70\u20138.","journal-title":"Respiration"},{"issue":"3","key":"3627_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type\u00a02 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205\u201314.","journal-title":"N Engl J Med"},{"key":"3627_CR53","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/COPD.S312560","volume":"16","author":"E Mekov","year":"2021","unstructured":"Mekov E, Nu\u00f1ez A, Sin DD, et al. Update on asthma\u2013COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783\u201399.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3627_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12931-019-1198-4","volume":"20","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Almasi\u2011Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma\u2011COPD overlap (ACO) in the general population: a systematic review and meta\u2011analysis. Respir Res. 2019;20(1):229.","journal-title":"Respir Res"},{"issue":"1","key":"3627_CR55","first-page":"1139","volume":"11","author":"B Ding","year":"2016","unstructured":"Ding B, DiBonaventura M, Karlsson N, Ling X. Asthma\u2011chronic obstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and Wellness Surveys. Int J Chron Obstruct Pulmon Dis. 2016;11(1):1139\u201350.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3627_CR56","unstructured":"Song P, Zha M, Xia W, Zeng C, Zhu Y. Asthma\u2013chronic obstructive pulmonary disease overlap in China: Prevalence, associated factors and comorbidities in middle\u2011aged and older adults. Figshare. 2020. https:\/\/figshare.com\/articles\/journal_contribution\/Asthma-chronic_obstructive_pulmonary_disease_overlap_in_China_prevalence_associated_factors_and_comorbidities_in_middle-aged_and_older_adults\/11761584\/2. Accessed Mar 12, 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03627-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:11Z","timestamp":1785517631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03627-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3627"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03627-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dan Shen and Yingrui Xu are employees of Sanofi and may hold shares and\/or stock options in the company. Kailing Wang used to be an employee of Sanofi during the work. Ke Huang, Yanan Cui, Tingting Huang, Xiaoning He and Ting Yang declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the ethics committee of China\u2013Japan Friendship Hospital (Approval No. 2024-KY-367) and Tianjin University (Approval No. TJUE-2024-473), with informed consent waived for the participants.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}